[HTML][HTML] Risk factors for the development of severe bacterial infection in patients with multiple myeloma during chemotherapy with bortezomib containing regimens
SY Hyun, JE Jang, Y Kim, DY Hwang, SJ Kim, YR Kim… - Blood, 2013 - Elsevier
Background The aim of this study is to identify risk factors associated with the development
of severe bacterial infection (SBI) in patient with multiple myeloma (MM) during treatment …
of severe bacterial infection (SBI) in patient with multiple myeloma (MM) during treatment …
[HTML][HTML] Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple …
SY Hyun, SH Han, SJ Kim, JE Jang, Y Kim… - Journal of Korean …, 2016 - ncbi.nlm.nih.gov
The aim of this study was to identify the risk factors associated with severe bacterial infection
(SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens …
(SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens …
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens
SH Jung, JS Ahn, SJ Kang, DH Yang, YK Kim, HJ Kim… - 2012 - ashpublications.org
Abstract 5042 Bortezomib is a proteasome inhibitor with potent antimyeloma activity in
relapsed/refractory multiple myeloma (MM) patients. We evaluated the type and factors …
relapsed/refractory multiple myeloma (MM) patients. We evaluated the type and factors …
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens
SH Jung, SY Bae, JS Ahn, SJ Kang, DH Yang… - International Journal of …, 2013 - Springer
Bortezomib is a proteasome inhibitor with potent antimyeloma activity in relapsed/refractory
multiple myeloma (MM) patients. We evaluated the types and factors affecting the onset of …
multiple myeloma (MM) patients. We evaluated the types and factors affecting the onset of …
Incidence and risk factors for bacterial infection in newly diagnosed multiple myeloma patients undergoing treatment with bortezomib, lenalidomide, and …
e20008 Background: Infection is an important cause of morbidity and mortality in newly
diagnosed multiple myeloma (NDMM), but the risk of infection using novel treatment …
diagnosed multiple myeloma (NDMM), but the risk of infection using novel treatment …
Bacterial infection among patients with multiple myeloma treated with bortezomib-based induction therapy: Real-world experience in an asian cancer center
Background The treatment landscape for multiple myeloma (MM) has progressed
significantly, and over the past decade, bortezomib-based induction therapy has been a …
significantly, and over the past decade, bortezomib-based induction therapy has been a …
The infection rate in new diagnosis and relapsed/refractory multiple myeloma patients who had bortezomib-based chemotherapy and relationship between …
M PAMUKCUOGLU, NA Baysal… - The European Research …, 2021 - dergipark.org.tr
Objectives: Multiple Myeloma (MM) is a disease caused by the clonal proliferation of plasma
cells. In recent years, proteozom inhibitors, immunomodulatory agents and monoclonal …
cells. In recent years, proteozom inhibitors, immunomodulatory agents and monoclonal …
[HTML][HTML] Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib …
J Li, Y Li, B Huang, D Zheng, M Chen… - Cell biochemistry and …, 2015 - Springer
Bortezomib is effective in the therapy of multiple myeloma (MM), but causes infections that
are different from those associated with conventional chemotherapy. It is important to identify …
are different from those associated with conventional chemotherapy. It is important to identify …
[HTML][HTML] Infectious Complications in Multiple Myeloma Patients Receiving Various Antitumor Regimens
AA Novikova, GA Klyasova, EO Gribanova… - Clinical …, 2019 - old.bloodjournal.ru
Aim. To study infectious complications and factors attributable to them as reported in multiple
myeloma (MM) patients in the framework of state-of-the-art anticancer therapy. Materials & …
myeloma (MM) patients in the framework of state-of-the-art anticancer therapy. Materials & …
Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma
Infections are an important cause of morbidity and mortality in newly diagnosed multiple
myeloma (NDMM), but the real-world risk using modern induction regimens such as …
myeloma (NDMM), but the real-world risk using modern induction regimens such as …